| Literature DB >> 21339939 |
Fengying Quan1, Guangwei Liu, Liang Wang, Xuefeng Wang.
Abstract
PURPOSE: The purpose of this study is to investigate the distribution and antimicrobial susceptibility of pathogenic bacteria in inpatients with pulmonary infection in the neurological intensive care unit (NICU).Entities:
Keywords: drug resistance; neurological intensive care unit; nosocomial infection; pulmonary infection
Year: 2011 PMID: 21339939 PMCID: PMC3039010 DOI: 10.2147/TCRM.S15730
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
The demographics, underlying diseases, and outcomes of inpatients
| Median age | 61.2 years (16–89) |
| Gender | |
| Male | 225 (52.6%) |
| Female | 203 (47.4%) |
| Admission diagnosis | |
| Cerebral infarction | 140 (32.7%) |
| Intracerebral hemorrhage | 69 (16.1%) |
| Subarachnoid hemorrhage | 38 (8.9%) |
| Encephalitis | 48 (11.2%) |
| Tuberculous meningitis | 15 (3.5%) |
| Multiple sclerosis | 27 (6.3%) |
| Guillain–Barre syndrome | 20 (4.7%) |
| Acute myelitis | 12 (2.8%) |
| Status epilepticus | 35 (8.2%) |
| Encephalopathy | 24 (5.6%) |
| Median length of NICU stay | 7.4 days (2–30) |
| Outcome | |
| Discharged | 398 (93.0%) |
| Mortality | 30 (7.0%) |
The distribution and ratio of pulmonary infection pathogens in NICU
| Gram-negative bacteria | 276 | 69.0 |
| | 82 | 20.5 |
| | 62 | 15.5 |
| | 48 | 12.0 |
| | 14 | 3.5 |
| | 10 | 2.5 |
| | 6 | 1.5 |
| | 4 | 1.0 |
| | 4 | 1.0 |
| Others | 46 | 11.5 |
| Gram-positive bacteria | 40 | 10.0 |
| | 10 | 2.5 |
| | 10 | 2.5 |
| | 7 | 1.75 |
| Others | 13 | 3.25 |
| Fungus | 84 | 21.0 |
| | 49 | 12.25 |
| | 15 | 3.75 |
| Others | 20 | 5.0 |
Resistance rates of common Gram-negative bacilli to antibiotics (%)
| Ampicillin | 100 | 100 | 100 |
| Co-trimoxazole | 100 | 100 | 100 |
| Amoxicillin | 100 | – | 100 |
| Cephalothin | 100 | – | 100 |
| Cefotaxime | 100 | – | 100 |
| Netilmicin | 100 | – | 100 |
| Cefuroxime | 100 | – | 100 |
| Ticarcillin | 100 | 95.16 | 100 |
| Piperacillin | 100 | 61.29 | 100 |
| Cefazolin | 90 | 100 | 100 |
| Ampicillin/sulbactam | 90 | 100 | 87.50 |
| Gentamicin | 82.72 | 75.38 | 72.92 |
| Nitrofurantoin | 80 | 100 | 100 |
| Ceftriaxone | 76.25 | 100 | 100 |
| Cefepime | 72.84 | 55.38 | 55.32 |
| Trimethoprim/sulfamethoxazole | 72.5 | 100 | 86.96 |
| Aztreonam | 72.5 | 67.21 | 78.26 |
| Tetracycline | 72 | 100 | 100 |
| Ceftazidime | 71.6 | 66.15 | 77.08 |
| Ceftizoxime | 62 | 96.55 | 76.67 |
| Ticarcillin/clavulanic acid | 60.78 | 95.08 | 68.97 |
| Tobramycin | 60.49 | 73.85 | 60.42 |
| Amikacin | 56.25 | 37.70 | 34.78 |
| Ciprofloxacin | 54.34 | 76.92 | 75 |
| Levofloxacin | 51.25 | 59.02 | 17.02 |
| Piperacillin/tazobactam | 16.25 | 28.13 | 20 |
| Cefotetan | 10 | 100 | 100 |
| Ertapenem | 10 | – | – |
| Imipenem | 1.23 | 35.38 | 2.08 |
| Cefoxitin | 0 | – | 100 |
| Meropenem | 0 | 43.10 | 0 |
Resistance rates of common Gram-positive cocci to antibiotics (%)
| Penicillin G | 100 | 100 | 100 |
| Erythromycin | 100 | 80 | 100 |
| Azithromycin | 100 | 80 | 100 |
| Clarithromycin | 100 | 80 | 100 |
| Ciprofloxacin | 100 | 70 | 100 |
| Tetracycline | 100 | 20 | 14.29 |
| Amoxicillin | 90 | 90 | 100 |
| Ampicillin/sulbactam | 90 | 90 | 100 |
| Cefaclor | 90 | 90 | 100 |
| Oxacillin | 90 | 90 | 85.71 |
| Gentamicin | 90 | 50 | 100 |
| Imipenem | 88.89 | 90 | 100 |
| Ceftriaxone | 88.89 | 90 | 100 |
| Cefuroxime | 88.89 | 90 | 100 |
| Cefotaxime | 88.89 | 90 | 100 |
| Rifampicin | 70 | 40 | 14.29 |
| Fosfomycin | 44.44 | 10 | 100 |
| Trimethoprim/sulfamethoxazole | 42.86 | 90 | 60 |
| Moxifloxacin | 33.33 | 10 | 0 |
| Fusidate | 22.22 | 10 | 0 |
| Dalfopristin | 0 | 0 | 0 |
| Linezolid | 0 | 0 | 0 |
| Teicoplanin | 0 | 0 | 0 |
| Vancomycin | 0 | 0 | 0 |